Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SinotherapeuticsSHSE:688247 +7.68%85 EV-to-EBITDA is 54.50 as of Sep. 21, 2026, which is 25% above its 10-year median of 43.51. GuruFocus rates SHSE:688247 with a GF Score™ of 85/100 and a GF Value™ of ¥9.63 (Fairly Valued). The stock has 5 warning signs investors should review. Among 745 Drug Manufacturers companies, Sinotherapeutics ranks worse than 91.68% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sinotherapeutics's enterprise value is ¥3,701.6 Mil.
Sinotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ¥67.9 Mil. Therefore, Sinotherapeutics's EV-to-EBITDA for today is 54.50.
The historical rank and industry rank for Sinotherapeutics's EV-to-EBITDA or its related term are showing as below:
SHSE:688247'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 22.83 Med: 43.51 Max: 112.38
Current: 54.5
During the past 7 years, the highest EV-to-EBITDA of Sinotherapeutics was 112.38. The lowest was 22.83. And the median was 43.51.
SHSE:688247's EV-to-EBITDA is ranked worse than 91.68% of 745
companies
in the Drug Manufacturers industry
Industry Median: 12.56
vs SHSE:688247: 54.50
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sinotherapeutics's PE Ratio (TTM) for today is calculated as:
Sinotherapeutics's share price for today is ¥9.96.
Sinotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.070.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Sinotherapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sinotherapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinotherapeutics EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sinotherapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sinotherapeutics's EV-to-EBITDA falls into.
Sinotherapeutics's current Enterprise Value is ¥3,701.6 Mil.
Sinotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥67.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinotherapeutics (SHSE:688247) has a EV-to-EBITDA of 54.50 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sinotherapeutics. This is 25% above median its historical median of 43.51. Over the past decade, Sinotherapeutics' EV-to-EBITDA has ranged from 22.83 to 112.38. According to the industry distribution chart, Sinotherapeutics ranks #683 out of 745 companies in the Drug Manufacturers industry, placing it in the top 91.7%.
Is Sinotherapeutics' EV-to-EBITDA too high?
Sinotherapeutics' current EV-to-EBITDA of 54.50 is 25% above median its 10-year median of 43.51. Over the past 10 years, this metric has ranged from a low of 22.83 to a high of 112.38. The Drug Manufacturers industry median EV-to-EBITDA is 12.56. Sinotherapeutics' value of 54.50 is 333.9% above this industry median. Based on the distribution chart, Sinotherapeutics ranks #683 out of 745 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sinotherapeutics has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinotherapeutics' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sinotherapeutics ranks #683 out of 745 companies for EV-to-EBITDA. This places Sinotherapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 12.56. Sinotherapeutics' value of 54.50 is 333.9% above this benchmark. Historically, Sinotherapeutics' own EV-to-EBITDA has ranged from 22.83 to 112.38 over the past decade. While the company's 10-year median is 43.51 vs. the industry median of 12.56, Sinotherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.56, based on 745 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinotherapeutics's current EV-to-EBITDA of 54.50 is 333.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sinotherapeutics. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinotherapeutics's current EV-to-EBITDA is 54.50, which is 25% above median its own 10-year median of 43.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sinotherapeutics (SHSE:688247) is currently considered Fairly Valued. The stock's GF Value™ is ¥9.63, compared to a current price of ¥9.96 — trading 3.4% above its estimated fair value. The current EV-to-EBITDA is 54.50, which is 25% above median its 10-year median of 43.51 and 333.9% above the Drug Manufacturers industry median of 12.56. Sinotherapeutics' overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sinotherapeutics (SHSE:688247), the current EV-to-EBITDA is 54.50 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinotherapeutics (SHSE:688247) Overvalued in 2026?
Based on GuruFocus' analysis, Sinotherapeutics stock appears to be overvalued.
The current stock price of ¥9.96 is trading 3.4% above its estimated GF Value™ of ¥9.63.
GuruFocus considers Sinotherapeutics to be Fairly Valued.
Key valuation signals for SHSE:688247:
EV-to-EBITDA: 54.50 (25% above median its 10-year median of 43.51)
GF Value™: ¥9.63 vs. price of ¥9.96 (3.4% above fair value)
Industry Position: 333.9% above the Drug Manufacturers median (#683 of 745)
No single metric tells the full story. See the SHSE:688247 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688247 has been successfully added to your 
